Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($0.01), $0.28 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $27.6 million versus the consensus estimate of $24.55 million.

2015 Financial Guidance

Vanda is updating its 2015 financial guidance and expects to achieve the following financial objectives in 2015:

• Combined net product sales from both HETLIOZ® and Fanapt® of between $100 million and $115 million, compared to prior guidance of $95 million to $110 million.
• HETLIOZ® net product sales of between $40 million to $45 million.
• Fanapt® net product sales of between $60 million to $70 million, compared to prior guidance of $55 million to $65 million.
• Non-GAAP Operating expenses, excluding cost of goods sold, of between $100 million and $110 million, compared to prior guidance of $105 million to $120 million.

Non-GAAP Operating expenses also excludes:

• Intangible asset amortization expense of $13.0 million.
• Stock-based compensation of between $8.5 million and $10.5 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.